Syncom Formulations (India) Ltd
₹13.44
(-3.86%)
Thu, 19 Feb 2026, 02:09 am
Health Technology
Pharmaceuticals: Major
24.5KSyncom Formulations (India) Return on Equity (ROE) History
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 6.49 | 5.33 | 4.78 | 3.47 | 5.35 | 219.64 | 33.53 | 29.87 | 34.12 | 34.32 | 16.77 | 14.07 | 8.82 | 7.60 | 3.94 | 8.39 | 46.91 | 27.29 | 41.52 | 31.28 |
| Price to book ratio | 1.13 | 0.65 | 0.46 | 0.21 | 0.62 | 0.84 | 1.41 | 1.93 | 4.76 | 3.34 | 1.60 | 1.35 | 0.62 | 0.64 | 0.39 | 1.31 | 4.13 | 2.17 | 3.65 | 4.52 |
| Price to sales ratio | 0.63 | 0.38 | 0.26 | 0.17 | 0.29 | 0.63 | 1.04 | 1.52 | 2.21 | 2 | 0.97 | 0.86 | 0.49 | 0.46 | 0.28 | 1.02 | 4.26 | 2.46 | 4.05 | 3.38 |
| Price to cash flow ratio | 13.09 | 4.49 | 2.93 | 0 | 0 | 0 | 18.16 | 27.93 | 46 | 249.53 | 6.87 | 33.99 | 25.71 | 20.51 | 10.40 | 0 | 61.99 | 74.05 | 0 | 68.51 |
| Enterprise value | 372.75M | 265.56M | 218.8M | 173.25M | 237.35M | 469.43M | 1.19B | 1.68B | 3.22B | 3.34B | 1.74B | 1.59B | 822.6M | 851.11M | 497.8M | 2.33B | 9.44B | 5.6B | 9.92B | 14.61B |
| Enterprise value to EBITDA ratio | 7.53 | 6.07 | 5.95 | 4.44 | 5.29 | 0 | 68.54 | 22.61 | 19.81 | 26.72 | 14.84 | 14.01 | 11.12 | 11.58 | 4.30 | 7.11 | 50.50 | 30.40 | 37.99 | 31.06 |
| Debt to equity ratio | 0.21 | 0.21 | 0.19 | 0.26 | 0.17 | 0.06 | 0.08 | 0.02 | 0.03 | 0.06 | 0.05 | 0.11 | 0.10 | 0.07 | 0.01 | 0.33 | 0.26 | 0.32 | 0.25 | 0.01 |
| Return on equity % | 0 | 12.84 | 9.79 | 6.60 | 9.18 | 0.30 | 4.24 | 6.61 | 10.20 | 9.99 | 9.92 | 9.57 | 7.23 | 8.72 | 10.24 | 17.51 | 9.66 | 8.39 | 9.30 | 15.69 |
Syncom Formulations (India) Ltd Return on Equity
The Syncom Formulations (India) Ltd Return on Equity is a key financial metric used by investors to evaluate Syncom Formulations (India) Ltd's valuation, profitability, and overall financial performance. Tracking the Syncom Formulations (India) Ltd Return on Equity helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Syncom Formulations (India) Ltd (NSE: SYNCOMF, BSE: 524470) is currently trading at ₹13.44, with a market capitalization of ₹13.18B. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Syncom Formulations (India) Ltd Return on Equity is essential for fundamental analysis.
Syncom Formulations (India) Ltd Return on Equity Current Value
The current Syncom Formulations (India) Ltd Return on Equity stands at 15.69.
The latest Syncom Formulations (India) Ltd Return on Equity has increased compared to the previous period, indicating rising valuation or improved investor sentiment.
Syncom Formulations (India) Ltd Return on Equity Historical Trend
The Syncom Formulations (India) Ltd Return on Equity has shown the following historical trend:
- 2024: 15.69
- 2023: 9.30
- 2022: 8.39
- 2021: 9.66
- 2020: 17.51
The recent rise in Syncom Formulations (India) Ltd Return on Equity suggests strengthening valuation trends and improving market sentiment.
What Syncom Formulations (India) Ltd Return on Equity Indicates for Investors
The Syncom Formulations (India) Ltd Return on Equity plays a crucial role in understanding the company's financial health and valuation.
ROE indicates how efficiently the company generates returns for shareholders.
Syncom Formulations (India) Ltd Return on Equity Analysis Summary
The Syncom Formulations (India) Ltd Return on Equity remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Syncom Formulations (India) Ltd Return on Equity should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Syncom Formulations (India) Ltd Return on Equity helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800